The results from two Phase IIb paediatric studies investigating the safety, efficacy, and...
- ECCMID 2018: Avycaz set for paediatric label expansion following Phase IIb trials
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
- Public-private partnerships continue to play a critical role in influenza vaccine R&D
- Pain takes largest share of clinical trials in 2017
ECCMID 2018: Avycaz set for paediatric label expansion following Phase IIb trials
The results from two Phase IIb paediatric studies investigating the safety, efficacy, and pharmacokinetics of Avycaz for the treatment of complicated intra-abdominal infections and complicated urinary tract infections were presented at the 2018 European Congress of Clinical Microbiology and Infectious Diseases.
Deals this week: Aeglea BioTherapeutics, BerGenBio, Evelo Biosciences
Aeglea BioTherapeutics intends to raise funds for its ongoing research and development (R&D), production and regulatory activities and other purposes.
CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of anti-PD-1 and –PD-L1 checkpoint inhibitors (CPIs) in the clinic.
ILC 2018: Madrigal Therapeutics’ MCL-3196 reduces liver fat in NASH patients
Clinical efficacy data for Madrigal Therapeutics’ Phase II NASH therapeutic, MCL-3196, which was presented at the 2018 International Liver Congress (ILC) in Paris, France, demonstrated the investigational drug met its primary endpoint of liver fat reduction versus a placebo.
ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
Evidence that Allergan’s Phase III drug candidate, cenicriviroc, may benefit non-alcoholic steatohepatitis (NASH) patients was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Deals this week: Intec Pharma, FIMECS, Mereo Biopharma Group
Israeli drug development company Intec Pharma Ltd has issued an underwritten public offering of shares of its common stock.
Deals this week: Biohaven, Cellectis, Antisense Therapeutics
US-based biopharmaceutical company Biohaven Pharmaceutical Holding Company Ltd has opted to issue two million shares of its common stock in a public offering.
Hizentra for the Treatment of Patients with CIDP
Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.